Zobrazeno 1 - 10
of 10
pro vyhledávání: '"William J. Edenfield"'
Metastatic ghost cell odontogenic carcinoma: description of a case and search for actionable targets
Publikováno v:
Rare Tumors, Vol 7, Iss 3 (2015)
Ghost cell odontogenic carcinoma (GCOC) is an exceedingly rare malignant tumor on the spectrum of already uncommon odontogenic or dentinogenic tumors. We describe here the case of metastatic GCOC in a patient with a history of recurrent dentinogenic
Externí odkaz:
https://doaj.org/article/1b5a0199b6fb4454bdabe869dad3e735
Autor:
Meena Okera, Brian A. Van Tine, Joleen M. Hubbard, Minal Barve, Erika Hamilton, Monica M. Mita, Frances Valdes-Albini, Daniel Ahn, Admasu Mamuye, Joshua Pelham, Amy Yuet, Diana Yurewicz, Yanning Liu, Andres Machado Sandri, William J. Edenfield, Aki Morikawa, William Gradishar, Rajiv Kumar, Zev A. Wainberg
Publikováno v:
Cancer Research. 83:OT2-11
MT-5111 is a 55kD engineered toxin body targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 works by internalizing, self
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::371f690d9bd1864fa82d1608053510e3
https://doi.org/10.1158/1538-7445.sabcs22-ot2-11-01
https://doi.org/10.1158/1538-7445.sabcs22-ot2-11-01
Autor:
Alex Kesic, Avery Funkhouser, Jonah Shealy, Julie Martin, W. Larry Gluck, William J. Edenfield, Anna Blenda
Publikováno v:
Cancer Research. 83:P2-26
Glycobiology has proved to be a new frontier in oncology research in recent years. One sector of glycobiology involves examining glycan expression of cancerous cells. Glycans are complex carbohydrates found on cell surfaces, and patterns of aberrant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f1807bf75b32f4b00165fc9fb776211
https://doi.org/10.1158/1538-7445.sabcs22-p2-26-22
https://doi.org/10.1158/1538-7445.sabcs22-p2-26-22
Autor:
Mary-Ellen Taplin, Karen J. Ferrante, Khalid Mamlouk, William J. Edenfield, Luke T. Nordquist, Alan J. Koletsky, Nicholas J. Vogelzang, Joseph J. Stephenson, Roberto Pili, Franklin Chu, Matthew B. Rettig, Mario A. Eisenberger, Bruce Montgomery
Appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0131dafb3a9e6630df68c872cbf7d6fa
https://doi.org/10.1158/1078-0432.22458224
https://doi.org/10.1158/1078-0432.22458224
Autor:
Mary-Ellen Taplin, Karen J. Ferrante, Khalid Mamlouk, William J. Edenfield, Luke T. Nordquist, Alan J. Koletsky, Nicholas J. Vogelzang, Joseph J. Stephenson, Roberto Pili, Franklin Chu, Matthew B. Rettig, Mario A. Eisenberger, Bruce Montgomery
Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an increase in AR protein degradation. These open-label phase I and II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6f3751f5bff82843638e91d05f304de
https://doi.org/10.1158/1078-0432.c.6523877.v1
https://doi.org/10.1158/1078-0432.c.6523877.v1
Publikováno v:
Biophysical Journal. 122:330a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4ad36210c1ed3e8b6ac76a3fee31dc0
https://doi.org/10.1016/j.bpj.2022.11.1844
https://doi.org/10.1016/j.bpj.2022.11.1844
Autor:
Amer M. Zeidan, Rachel J. Cook, Rodolfo Bordoni, James R. Berenson, William J. Edenfield, Sanjay Mohan, Gongfu Zhou, Ekaterine Asatiani, Nithya Srinivas, Michael R. Savona
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(7)
The Janus kinase (JAK)/signal transducers and activators of transcription pathway has been implicated in the pathogenesis and progression of various hematologic malignancies. JAK1-regulated cytokines stimulate proliferation and growth of malignant ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72a596a4e7e09dc03674d62c394704e3
https://pubmed.ncbi.nlm.nih.gov/35260349
https://pubmed.ncbi.nlm.nih.gov/35260349
Autor:
Avery T. Funkhouser, Alexander M. Strigenz, Bailey B. Blair, Andrew P. Miller, Jonah C. Shealy, Joseph A. Ewing, Julie C. Martin, Christopher R. Funk, William J. Edenfield, Anna V. Blenda
Publikováno v:
Cancers; Volume 14; Issue 11; Pages: 2781
To investigate a potential role for galectins as biomarkers that enable diagnosis or prognostication of breast or non-small cell lung cancer, the serum levels of galectins -1, -3, -7, -8, and -9 of cancer patients determined by ELISA assays were comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10dd5ff2ddd23ed694a3eb61bb1ca9da
https://doi.org/10.3390/cancers14112781
https://doi.org/10.3390/cancers14112781
Autor:
Patricia LoRusso, Drew Rasco, Johanna Bendell, Jasgit Sachdev, Ramesh Ramanathan, Glenn Weiss, Pamela Munster, William J. Edenfield, Kejian Liu, Anne Blackwood-Chirchir, Jorge DiMartino, Daniel D. Von Hoff
Publikováno v:
Molecular Cancer Therapeutics. 12:A120-A120
Background: CC-486, an oral formulation of 5-azacitidine, induces global genomic hypomethylation and clinical responses in MDS patients at doses of 200 mg and 300 mg/day for 14 or 21/28 days with acceptable safety. This non-randomized, multi-center P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c57f7f152581e25d8e437d3f79c6dcbd
https://doi.org/10.1158/1535-7163.targ-13-a120
https://doi.org/10.1158/1535-7163.targ-13-a120
Autor:
Rapp SR; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX. srapp@wakehealth.edu., Case LD; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Peiffer A; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Naughton MM; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Chan MD; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Stieber VW; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Moore DF Jr; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Falchuk SC; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Piephoff JV; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Edenfield WJ; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Giguere JK; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Loghin ME; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX., Shaw EG; Stephen R. Rapp, L. Doug Case, Ann Peiffer, Michelle M. Naughton, Michael D. Chan, and Edward G. Shaw, Wake Forest School of Medicine and Wake Forest Community Clinical Oncology Program Research Base; Volker W. Stieber, Novant Health System, Winston-Salem, NC; Dennis F. Moore Jr, Wichita Community Clinical Oncology Program, Wichita, KS; Steven C. Falchuk, Christiana Care Health Services, Newark, DE; James V. Piephoff, Mercy Hospital, St Louis, MO; William J. Edenfield and Jeffrey K. Giguere, Cancer Center of Carolinas, Greenville, SC; and Monica E. Loghin, University of Texas MD Anderson Cancer Center, Houston, TX.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2015 May 20; Vol. 33 (15), pp. 1653-9. Date of Electronic Publication: 2015 Apr 20.